INS and type 1 diabetes mellitus: However, compared with placebo, SGLT2i treatment was associated with a significantly higher rate of GTIs at 24–26 weeks (4.14[2.72, 6.29], P < 0.001) and 52 weeks (4.37 [3.15, 6.06], P < 0.001)] in patients with T1DM receiving insulin therapy (Table 3).